Keryx Biopharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch KERX and buy or sell other stocks, ETFs, and their options commission-free!

About KERX

Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. 

CEO
Jodie P. Morrison
CEOJodie P. Morrison
Employees
—
Employees—
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1998
Founded1998
Employees
—
Employees—

KERX Key Statistics

Market cap
404.49M
Market cap404.49M
Price-Earnings ratio
-4.41
Price-Earnings ratio-4.41
Dividend yield
—
Dividend yield—
Average volume
2.10M
Average volume2.10M
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$5.98
52 Week high$5.98
52 Week low
$2.47
52 Week low$2.47

Stock Snapshot

The current Keryx Biopharmaceuticals(KERX) stock price is $3.36, with a market capitalization of 404.49M. The stock trades at a price-to-earnings (P/E) ratio of -4.41.

During the trading day, Keryx Biopharmaceuticals(KERX) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for Keryx Biopharmaceuticals(KERX) stock has reached 0, versus its average volume of 2.1M.

The stock's 52-week range extends from a low of $2.47 to a high of $5.98.

The stock's 52-week range extends from a low of $2.47 to a high of $5.98.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.